Tofas Polydoros, Samarkos Michael, Piperaki Evangelia-Theophano, Kosmidis Christos, Triantafyllopoulou Ioanna-Dionysia, Kotsopoulou Maria, Pantazatou Aggeliki, Perlorentzou Stavroula, Poulli Anastasia, Vagia Maria, Daikos George L
First Department of Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens Greece.
Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens Greece.
Diagn Microbiol Infect Dis. 2017 Aug;88(4):335-341. doi: 10.1016/j.diagmicrobio.2017.05.003. Epub 2017 May 11.
Our aims were to identify factors associated with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) in patients with hematological malignancies and evaluate the outcome of the affected patients. Consecutive patients with hematological malignancies who developed PA BSI were identified. Subsequently, two case-control studies were performed to evaluate the risk factors (i) for PA BSI and (ii) for carbapenem resistant (CR) PA BSI. Patients' outcome was evaluated at 28 days after the onset of bacteraemia. A total of 64 patients with PA BSI (45 caused by CS and 19 by CR organisms) and 128 without PA BSI were enrolled. Patients with rapidly fatal disease, steroid use, neutropenia or prior surgery were more likely to develop PA BSI, whereas patients with previous hospitalization and prior use of fluoroquinolones were more likely to develop CR PA BSI. The 28-day mortality rate was 35.9%. Severity of sepsis was the only independent predictor of adverse outcome.
我们的目的是确定血液系统恶性肿瘤患者铜绿假单胞菌（PA）血流感染（BSI）的相关因素，并评估受影响患者的预后。确定了发生PA BSI的连续性血液系统恶性肿瘤患者。随后，进行了两项病例对照研究，以评估（i）PA BSI和（ii）碳青霉烯耐药（CR）PA BSI的危险因素。在菌血症发作后28天评估患者的预后。共纳入64例PA BSI患者（45例由敏感菌引起，19例由CR菌引起）和128例无PA BSI的患者。患有快速致命疾病、使用类固醇、中性粒细胞减少或既往有手术史的患者更易发生PA BSI，而既往有住院史和既往使用氟喹诺酮类药物的患者更易发生CR PA BSI。28天死亡率为35.9%。脓毒症的严重程度是不良预后的唯一独立预测因素。
